DekaBank Deutsche Girozentrale Boosts Holdings in DaVita Inc. $DVA

DekaBank Deutsche Girozentrale boosted its position in shares of DaVita Inc. (NYSE:DVA) by 8.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,013 shares of the company’s stock after buying an additional 1,084 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in DaVita were worth $1,991,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Concurrent Investment Advisors LLC bought a new stake in shares of DaVita in the first quarter valued at about $223,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of DaVita by 22.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company’s stock valued at $666,000 after acquiring an additional 800 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of DaVita by 7.9% in the first quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company’s stock valued at $8,452,000 after acquiring an additional 4,048 shares in the last quarter. OneDigital Investment Advisors LLC bought a new stake in shares of DaVita in the first quarter valued at about $200,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of DaVita in the first quarter valued at about $1,010,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

Shares of NYSE DVA opened at $129.27 on Friday. DaVita Inc. has a 12 month low of $122.93 and a 12 month high of $179.60. The stock has a market capitalization of $9.24 billion, a price-to-earnings ratio of 12.71, a PEG ratio of 0.93 and a beta of 1.13. The firm’s 50 day simple moving average is $132.02 and its 200-day simple moving average is $137.65.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the firm posted $2.00 EPS. The business’s revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of recent research reports. Barclays reduced their target price on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a report on Thursday, October 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a report on Friday. Bank of America lowered their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Truist Financial set a $140.00 price objective on DaVita in a research report on Tuesday, October 14th. Finally, Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $153.25.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.